Focus: Kailera Therapeutics is a clinical-stage biotech focused on peptide and small molecule therapeutics targeting metabolic diseases, with a recently public listing on Nasdaq following a strong 60%+ IPO debut in April 2026.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Cooling — net -5 jobs in 30d
7 added, 12 removed. Slower than typical.
Kailera represents a growth-stage opportunity for professionals seeking equity upside and the chance to build commercial infrastructure from clinical success, but with execution risk typical of newly public biotech.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Kailera Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Kailera Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
KLRA Insider Trading (Kailera Therapeutics, Inc. stock) - StockInvest.us
KLRA Insider Trading (Kailera Therapeutics, Inc. stock) StockInvest.us
Kailera Therapeutics debut marks largest biotech IPO since 2021 amid weight loss race - MSN
Kailera Therapeutics debut marks largest biotech IPO since 2021 amid weight loss race MSN
Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy - Sahm
Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy Sahm
Fierce Pharma Asia—Merck’s PD-1xVEGF data; Zai Lab’s global view; Kailera’s record IPO - Fierce Pharma
Fierce Pharma Asia—Merck’s PD-1xVEGF data; Zai Lab’s global view; Kailera’s record IPO Fierce Pharma
Bain Capital Life Sciences Secures Board Role at Kailera Therapeutics with 17.4% Stake - TradingView
Bain Capital Life Sciences Secures Board Role at Kailera Therapeutics with 17.4% Stake TradingView
BCPE Perseus Investor Takes Activist Stake at Kailera Therapeutics with 20.3% Stake - TradingView
BCPE Perseus Investor Takes Activist Stake at Kailera Therapeutics with 20.3% Stake TradingView
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles